RESOLVED2

The development of a cancer drug is currently long, costly and requires the involvement of several thousand patients. Yet only 5% of these drugs will be approved for cancer treatment.
RESOLVED2 is a machine-learning method that predicts the approval of a drug at the end of a Phase I clinical trial. Phase I clinical studies are very early in the development of a drug, and RESOLVED2 requires an average of only 30 patients to make predictions. When RESOLVED2 predicts that a treatment will be approved, 73% of the treatments are indeed approved within 6 years, while the others are during the subsequent years
RESOLVED2 is also correct for 92% of treatments that will not be approved in 6 years. RESOLVED2 has the potential to reduce the number of patients to be included in clinical trials, by increasing the likelihood of routine use of treatment from 5% to 73%. A prospective evaluation is planned to confirm the usefulness of routine use of RESOLVED2.

RESOLVED2 is easy to use. Fill this form to get the approval predictions of your drug.

The treatment's name
Did this study include patients with an enrichment in a specific tumor type?
Did this study planned a dose expansion cohort?
Did this study consider molecular biomarkers for patients selection?
Were there complete responses observed?
Is the drug an antibody?
Is the drug a BCRP-ABCG2 inhibitors?
Is the drug a cytochrome P 450/CYP2C8 substrate?
Is the drug a cytochrome P 450/CYP2C9 substrate?
Is the drug a weak cytochrome P 450/CYP2D6 inhibitor?
Is the drug a cytochrome P 450/CYP3A inducer?
Is the drug a cytochrome P 450/CYP3A4 substrate?
Is the drug a cytochrome P450 inhibitor?
Is the drug a hypotensive agent?
Is the drug a kinase inhibitor?
Is the drug used as a miscellaneous skin and mucous membrane agents?
Is the drug a nucleic acid synthesis inhibitor?
Is the drug a P-glycoprotein/ABCB1 inhibitor?
Is the drug a P-glycoprotein/ABCB1 substrate?
Is the drug a protein?
Is the drug a purine analogue?
Is the drug a transferase?
Does the drug target the C1q sub-complement subunit A?
Does the drug target DNA?
Does the drug target DNA polymerase alpha catalytic subunit?
Does the drug target histone deacetylase 1?
Does the drug target the low affinity immunoglobulin gamma Fc region receptor II-b?
Does the drug target PDGFR-alpha 1?
Does the drug target PD-L1?
Has the drug already been approved? Enter the number of months [1-120]
www.000webhost.com